ES2985391T3 - Métodos y composiciones para el tratamiento de la infección por hepatitis B - Google Patents

Métodos y composiciones para el tratamiento de la infección por hepatitis B Download PDF

Info

Publication number
ES2985391T3
ES2985391T3 ES19799463T ES19799463T ES2985391T3 ES 2985391 T3 ES2985391 T3 ES 2985391T3 ES 19799463 T ES19799463 T ES 19799463T ES 19799463 T ES19799463 T ES 19799463T ES 2985391 T3 ES2985391 T3 ES 2985391T3
Authority
ES
Spain
Prior art keywords
hbsag
seq
bnp
loop
bionanoparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19799463T
Other languages
English (en)
Spanish (es)
Inventor
Renae Walsh
Stephen Locarnini
Hans Netter
Ronald Farquhar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melbourne Health
Original Assignee
Melbourne Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melbourne Health filed Critical Melbourne Health
Application granted granted Critical
Publication of ES2985391T3 publication Critical patent/ES2985391T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ES19799463T 2018-05-10 2019-05-09 Métodos y composiciones para el tratamiento de la infección por hepatitis B Active ES2985391T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862669663P 2018-05-10 2018-05-10
PCT/US2019/031483 WO2019217654A1 (en) 2018-05-10 2019-05-09 Methods and compositions for the treatment of hepatitis b infection

Publications (1)

Publication Number Publication Date
ES2985391T3 true ES2985391T3 (es) 2024-11-05

Family

ID=68466904

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19799463T Active ES2985391T3 (es) 2018-05-10 2019-05-09 Métodos y composiciones para el tratamiento de la infección por hepatitis B

Country Status (10)

Country Link
US (4) US11773141B2 (https=)
EP (2) EP3810625B1 (https=)
JP (2) JP2021522864A (https=)
KR (2) KR20250027279A (https=)
CN (3) CN120571006A (https=)
AU (2) AU2019267680C1 (https=)
CA (1) CA3099726A1 (https=)
ES (1) ES2985391T3 (https=)
PL (1) PL3810625T3 (https=)
WO (1) WO2019217654A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025244940A1 (en) * 2024-05-21 2025-11-27 Clearb Therapeutics Ltd. Methods and compositions for mrna- and dna-based treatment of hepatitis b infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US6740323B1 (en) * 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
CN100381463C (zh) * 2002-09-18 2008-04-16 中国人民解放军免疫学研究所 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途
EP2292642A1 (en) 2003-06-10 2011-03-09 Opal Therapeutics Pty Ltd Immunomodulating compositions, uses therefor and processes for their production
AU2015259470A1 (en) * 2014-05-16 2016-11-10 Yale University Virus like vesicles (VLVs) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection
WO2017059878A1 (en) * 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof

Also Published As

Publication number Publication date
AU2019267680C1 (en) 2025-02-27
EP3810625A1 (en) 2021-04-28
JP2024105291A (ja) 2024-08-06
CN119113097A (zh) 2024-12-13
AU2019267680B2 (en) 2024-07-25
KR20250027279A (ko) 2025-02-25
AU2019267680A1 (en) 2020-11-26
EP3810625B1 (en) 2024-05-22
EP3810625A4 (en) 2022-05-11
WO2019217654A1 (en) 2019-11-14
US12202862B2 (en) 2025-01-21
US11773141B2 (en) 2023-10-03
US20250333450A1 (en) 2025-10-30
KR20210010872A (ko) 2021-01-28
JP2021522864A (ja) 2021-09-02
EP4389222A2 (en) 2024-06-26
CN112513063A (zh) 2021-03-16
EP4389222A3 (en) 2024-08-28
CA3099726A1 (en) 2019-11-14
CN120571006A (zh) 2025-09-02
US20220002349A1 (en) 2022-01-06
US20250145669A1 (en) 2025-05-08
AU2024227453A1 (en) 2024-11-21
US20240150412A1 (en) 2024-05-09
PL3810625T3 (pl) 2025-03-03

Similar Documents

Publication Publication Date Title
Sominskaya et al. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes
IL259077B1 (en) Vaccines against hepatitis b virus
Pumpens et al. Construction of novel vaccines on the basis of the virus-like particles: Hepatitis B virus proteins as vaccine carriers
ES2965709T3 (es) Composición farmacéutica que incluye los antígenos de superficie y nucleocápside del virus de la hepatitis B
US20250333450A1 (en) Methods and compositions for the treatment of hepatitis b infection
WO2023015332A1 (en) Vaccine antigen
Wang et al. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice
BR112021009234A2 (pt) Composições imunogênicas para tratamento de hepatite b
HK40106023A (en) Methods and compositions for the treatment of hepatitis b infection
HK40040491A (en) Methods and compositions for the treatment of hepatitis b infection
HK40040491B (en) Methods and compositions for the treatment of hepatitis b infection
WO2025244940A1 (en) Methods and compositions for mrna- and dna-based treatment of hepatitis b infection
US20230079898A1 (en) Compositions and methods for treating and preventing hepatitis b and d
US20250197452A1 (en) Compositions and methods for treating and preventing hepatitis b and d
CN104474548B (zh) 预防和/或治疗慢性病毒感染的产品及方法
CN121737166A (zh) 用于预防或治疗乙肝病毒感染的单抗原或多抗原mRNA疫苗及其应用
BR112018069738B1 (pt) Composição farmacêutica, e, uso da mesma
PL230663B1 (pl) Szczepionka, sposob jej otrzymywania, wyizolowane chimeryczne bialko, wektor ekspresyjny, zestaw zawierajacy szczepionke oraz kompozycja do zastosowania w profilaktyce zakazen powodowanych przez HCV i/lub HBV
BR122024003112A2 (pt) Vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, uso de vetor viral, ácido nucleico isolado